Pharma channel feed – Endpoints News

Pharma channel feed

Alexion lines up a $60M option to buy Fortress-incubated biotech focused on a lucrative rare blood disease

7 years ago

J&J snags rights to a gene therapy portfolio from little MeiraGTx, a spinoff from Sam Waksal’s Kadmon

7 years ago

FDA blesses Merck’s PhIII effort to topple a mega-blockbuster — but there’s also a little biotech in this game

7 years ago

After a years-long reprieve, GSK is about to see Mylan’s generic carve into its mega-blockbuster Advair franchise

7 years ago

Voyager bags a 'transformational' $1.8B gene therapy pact with Neurocrine

7 years ago

Gottlieb lays out real world evidence priorities for 2019 with an eye on digital tools

7 years ago

Trevena forges plan to take once-rejected opioid across finish line, after 'productive' FDA meeting

7 years ago

The next 5 years: Higher R&D productivity is here to stay, emerging biotechs and new tech will have a big impact. But what about pricing?

7 years ago

EMA says symbolic goodbye to London HQ as it sets up shop in Amsterdam

7 years ago

Imbruvica regimen wins FDA approval as first non-chemotherapy treatment for untreated patients with common form of leukemia

7 years ago

Zai Lab nabs speedy China regulatory review for PARP drug Zejula

7 years ago

Scoop: GSK’s venture team at SR One in talks to spin off from its big pharma founder, now under new R&D management

7 years ago

Novartis sounds alarm on unsustainable drug supply chain if no-deal Brexit becomes reality

7 years ago

In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions

7 years ago

UK looks to ensure pharma submissions can continue under no deal Brexit

7 years ago

FDA opioid adcomm chair blasts agency for 'willful blindness that borders on the criminal'

7 years ago

Vertex sharpens focus on gene-editing in licensing deal with Merck KGaA

7 years ago

EMA wants docs to stop prescribing Eli Lilly’s cancer drug Lartruvo — and here's why

7 years ago

Microbiome test maker uBiome cuts 55 jobs to sharpen focus on drugs, partnerships — CNBC

7 years ago

With the FDA running out of funds, healthcare groups warn that the drug approval process will soon be derailed

7 years ago

FDA finalizes accelerated approval labeling guidance

7 years ago

TG Therapeutics' shares jump as umbralisib wins FDA's breakthrough status

7 years ago

FDA slaps a clinical hold on messenger RNA program for rare genetic disease

7 years ago

Celgene's top 20 upfront hits: Just how generous was Celgene in dealmaking? Let's review the records

7 years ago

First page Previous page 281 282 283284285 286 287 Next page Last page